RXi Pharmaceuticals Announces Positive Results with RXI-109 in the Eyes of Cynomolgus Monkeys as Part of a Dose Range Finding Study

MARLBOROUGH, Mass., May 2, 2014 -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced results from the assessment of connective tissue growth factor (CTGF) protein levels following intravitreal injection, of RXI‑109 in the eyes of cynomolgus monkeys, as part of a dose-range finding study to build the Company's ophthalmology franchise.

Synthetic Biologics to Discuss Phase II Results of Oral Estriol Candidate Trimesta™ for Relapsing-Remitting Multiple Sclerosis in Women

-- Conference Call Scheduled for Today, April 30, 2014 at 9 AM ET--

ROCKVILLE, Md., April 30, 2014 -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, will host a conference call today to discuss in further detail the topline Phase II study results of Trimesta™ (oral estriol), which the Company is developing as a once-daily adjunctive oral treatment for relapsing-remitting multiple sclerosis (RRMS) in women.

Pacific Biosciences of California, Inc. Announces First Quarter 2014 Financial Results

MENLO PARK, Calif., April 30, 2014 -- Pacific Biosciences of California, Inc. (PACB) today announced financial results for its first quarter ended March 31, 2014.

Revenue for the first quarter of 2014 totaled $11.6 million, compared to $5.6 million for the first quarter of 2013. First quarter 2014 revenue reflects the installation of nine PacBio^(R) RS II systems, compared to three PacBio^(R) RS systems during the first quarter of 2013. Total revenue for the first quarter of 2014 also included $1.7 million of revenue recognized pursuant to a development agreement the Company entered into with Roche Diagnostics during September 2013. The Company booked orders for nine PacBio RS II instruments during the quarter and ended the quarter with 13 instruments in backlog.

Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer

MM-398 in combination with 5-fluorouracil and leucovorin demonstrates statistically significant advantage compared to control arm
Plan to submit New Drug Application in 2014
Conference Call Scheduled for 8:30 a.m. ET Today

CAMBRIDGE, Mass., May 1, 2014 -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone.